- Trials with a EudraCT protocol (152)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
152 result(s) found for: Abdominal mass.
Displaying page 1 of 8.
EudraCT Number: 2009-016823-74 | Sponsor Protocol Number: CDZ-PE-002 | Start Date*: 2010-01-27 | |||||||||||
Sponsor Name:Cardoz AB | |||||||||||||
Full Title: An open pilot study to assess the effects of pemirolast on C-reactive protein levels in subjects with coronary artery disease. | |||||||||||||
Medical condition: Cardoz AB intends to develope pemirolast as an anti-inflammatory agent. The first intended indication for the product under development is abdominal aortic aneurysm. The proposed clinical study... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001719-39 | Sponsor Protocol Number: INN-CB-002 | Start Date*: 2008-07-23 | |||||||||||
Sponsor Name:Innocoll Technologies | |||||||||||||
Full Title: A Phase II, Single Dose, Blinded, Prospective Study to Investigate the Efficacy and Safety of the CollaRx® Bupivacaine Implant in Women following Abdominal Hysterectomy or other Nonlaparoscopic Ben... | |||||||||||||
Medical condition: To investigate the efficacy and safety of the CollaRx Bupivacaine Implant in women following abdominal hysterectomy or other nonlaparoscopic benign gynecological procedure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001787-71 | Sponsor Protocol Number: CCB-CRC-07-01 | Start Date*: 2008-02-11 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity | ||
Medical condition: Adiposity is another risk factor for developing cardiac insufficiency and myocardial hypertrophy. Probably the volume loading of the left ventricle, systemic inflammation, the fatty degeneration of... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-005166-31 | Sponsor Protocol Number: 3074K4-3340-WW | Start Date*: 2009-09-15 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Communit... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) SI (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001913-34 | Sponsor Protocol Number: TP-434-008 | Start Date*: 2013-08-16 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections | |||||||||||||
Medical condition: Complicated Intra-abdominal Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) EE (Completed) LT (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002208-21 | Sponsor Protocol Number: TP-434-025 | Start Date*: 2016-09-27 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections | |||||||||||||
Medical condition: Complicated Intra-abdominal Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) LV (Completed) EE (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004820-41 | Sponsor Protocol Number: MK-7625A-035 | Start Date*: 2017-08-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropen... | |||||||||||||
Medical condition: Complicated intra-abdominal infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) ES (Completed) HU (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003242-28 | Sponsor Protocol Number: D4280C00015 | Start Date*: 2015-05-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metron... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) GR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000979-16 | Sponsor Protocol Number: ESR-17-12784 | Start Date*: 2019-08-21 |
Sponsor Name:Dr. Guillem Cuatrecasas - CPEN S.L. | ||
Full Title: Dapagliflozin effect in the reduction of different abdominal fat layers in type 2 diabetic patients. | ||
Medical condition: Abdominal fat layers in type 2 diabetic patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005686-20 | Sponsor Protocol Number: 004 | Start Date*: 2012-08-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ... | |||||||||||||
Medical condition: Patients with Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022548-19 | Sponsor Protocol Number: TP-434-P2-cIAI-1 | Start Date*: 2011-05-09 | |||||||||||
Sponsor Name:Tetraphase Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult... | |||||||||||||
Medical condition: Community-acquired complicated intra-abdominal infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) BG (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015864-32 | Sponsor Protocol Number: DORIPED3001 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal In... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003773-34 | Sponsor Protocol Number: IT001-303 | Start Date*: 2018-11-23 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective Phase 3, double-blind, multicenter, randomized study of the efficacy and safety of sulopenem followed by sulopenem etzadroxil with probenecid versus ertapenem followed by ciprofloxaci... | ||
Medical condition: Complicated intra-abdominal infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) BG (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005384-31 | Sponsor Protocol Number: RSIv80 | Start Date*: 2021-03-19 | ||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||
Full Title: A single blinded multicenter randomized study comparing intubating conditions during rapid sequence induction with either suxamethonium 1.0 mg/kg or rocuronium 1.0 mg/kg in elderly patients (≥ 80 y... | ||||||||||||||||||
Medical condition: The aim of this study is to determine the proportion of excellent tracheal intubation conditions at 60 seconds after administration of either rocuronium 1.0 mg/kg or suxamethonium 1 mg/kg in patien... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023219-32 | Sponsor Protocol Number: GFT505-210-6 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:GENFIT | |||||||||||||||||||||||
Full Title: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety i... | |||||||||||||||||||||||
Medical condition: Patients with insulin resistance and abdominal obesity | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005604-54 | Sponsor Protocol Number: NXL104/2002 | Start Date*: 2009-04-10 | ||||||||||||||||
Sponsor Name:Novexel, S.A. | ||||||||||||||||||
Full Title: A prospective, multicentre, double-blind, randomized, comparative study to estimate the safety, tolerability and efficacy of NXL104/ceftazidime plus metronidazole vs. meropenem in the treatment of ... | ||||||||||||||||||
Medical condition: Complicated intra-abdominal infections (cIAI) in hospitalised adults | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004566-16 | Sponsor Protocol Number: CSPP100A2238 | Start Date*: 2007-03-12 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patie... | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-003395-22 | Sponsor Protocol Number: W3600586 | Start Date*: 2008-09-04 | |||||||||||
Sponsor Name:GlaxoSmithKline Consumer Healthcare | |||||||||||||
Full Title: The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition | |||||||||||||
Medical condition: Weight Loss | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001117-42 | Sponsor Protocol Number: DORI-NOS-2001 | Start Date*: 2007-10-18 | ||||||||||||||||
Sponsor Name:Janssen Cilag International NV | ||||||||||||||||||
Full Title: A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ven... | ||||||||||||||||||
Medical condition: ventilator-associated pneumonia complicated intra-abdominal infections | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
